PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10448891-2 1999 Stimulation of the cells with interleukin-1beta (2.5 ng/ml) resulted in a great increase of prostacyclin production, which was abolished by indomethacin (1 microM) or cycloheximide (2 microM). Cycloheximide 167-180 interleukin 1 beta Rattus norvegicus 30-47 27909743-11 2017 Both IL-1beta-induced NO production and L-arginine uptake were abolished in the presence of cycloheximide (1 muM). Cycloheximide 92-105 interleukin 1 beta Rattus norvegicus 5-13 26502574-4 2015 The IL-1 beta-mediated effects were also blocked by cycloheximide, an inhibitor of protein synthesis, as well as AMT and 1400W, which are iNOS inhibitors, and PTIO, an NO scavenger. Cycloheximide 52-65 interleukin 1 beta Rattus norvegicus 4-13 11311405-6 2001 The effect of IL-1beta was completely abolished when we treated cells with inhibitor of mitogen-activated protein kinases (MAPKs) (PD98059) (25 microM), phospholipase A(2) inhibitor mepacrine (30 microM) and protein synthesis inhibitor cycloheximide (CHX) (10 microg/ml). Cycloheximide 236-249 interleukin 1 beta Rattus norvegicus 14-22 11311405-6 2001 The effect of IL-1beta was completely abolished when we treated cells with inhibitor of mitogen-activated protein kinases (MAPKs) (PD98059) (25 microM), phospholipase A(2) inhibitor mepacrine (30 microM) and protein synthesis inhibitor cycloheximide (CHX) (10 microg/ml). Cycloheximide 251-254 interleukin 1 beta Rattus norvegicus 14-22 10807932-9 2000 Treatment of cells with SB203580 after inhibition of transcription by actinomycin D decreased the half-life of IL-1beta-induced PDGF-Ralpha mRNA from >4 to approximately 1.5 h. Moreover, pretreatment of cells with cycloheximide blocked induction of PDGF-Ralpha mRNA by IL-1beta, suggesting that de novo protein synthesis was required for PDGF-Ralpha mRNA stabilization. Cycloheximide 217-230 interleukin 1 beta Rattus norvegicus 111-119 14622206-9 2003 Whereas, IL-1 receptor antagonist and cycloheximide inhibited IL-1beta-evoked secretion of SP-like immunoreactivity (SP-li), actinomycin D decreased it significantly but did not entirely abolish it. Cycloheximide 38-51 interleukin 1 beta Rattus norvegicus 62-70 8977420-8 1997 Treatment with cycloheximide, a protein synthesis inhibitor, resulted in significant attenuation of the ability of IL-1 beta to up-regulate sPLA2 and cPLA2 gene expression as well as medium PLA2 activity. Cycloheximide 15-28 interleukin 1 beta Rattus norvegicus 115-124 9559891-6 1998 Cycloheximide (1 microM), a protein synthesis inhibitor, prevented iNOS protein expression, nitrite accumulation and the suppression of contractility by IL-1beta on the isolated aortic rings. Cycloheximide 0-13 interleukin 1 beta Rattus norvegicus 153-161 9786178-7 1998 Dexamethasone (0.5 mg/kg, s.c., 4 h) or cycloheximide (1.5 mg/kg, s.c., 6 h) significantly prevented the edema caused by des-Arg9-bradykinin (100 nmol) in rats treated with IL-1beta (81 +/- 5% and 59 +/- 3%) or TNF alpha (78 +/- 4% and 43 +/- 2%). Cycloheximide 40-53 interleukin 1 beta Rattus norvegicus 173-181 9786178-12 1998 injection of the IL-1beta or TNF alpha, produced up-regulation of B1 receptor-mediated paw edema, being this effect sensitive to dexamethasone and cycloheximide and to cyclo-oxygenase pathway. Cycloheximide 147-160 interleukin 1 beta Rattus norvegicus 17-25 8879343-9 1996 Thus, IL-1 beta controls iNOS gene expression at the transcriptional level, and an intermediate labile protein, whose synthesis is inhibited by cycloheximide, is required for IL-1 beta stimulated induction of iNOS mRNA transcription in WKY cells but not in SHR. Cycloheximide 144-157 interleukin 1 beta Rattus norvegicus 175-184 8949656-7 1996 Pretreatment with cycloheximide blocked IL 1 beta induced inhibition of ACh stimulated jejunal contraction, suggesting that a newly synthesised protein was involved in the effect. Cycloheximide 18-31 interleukin 1 beta Rattus norvegicus 40-49 8647111-7 1996 Northern blot analysis using rat EC iNOS cDNA as a probe revealed that cycloheximide treatment led to a marked accumulation of iNOS mRNA in the presence and absence of interleukin-1 beta. Cycloheximide 71-84 interleukin 1 beta Rattus norvegicus 168-186 7544689-8 1995 Simultaneous incubation of IL-1 beta with NG-monomethyl-L-arginine, genistein, calphostin C, cycloheximide, or actinomycin D completely inhibited the IL-1 beta induced NO production by cardiac myocytes. Cycloheximide 93-106 interleukin 1 beta Rattus norvegicus 27-36 7544689-8 1995 Simultaneous incubation of IL-1 beta with NG-monomethyl-L-arginine, genistein, calphostin C, cycloheximide, or actinomycin D completely inhibited the IL-1 beta induced NO production by cardiac myocytes. Cycloheximide 93-106 interleukin 1 beta Rattus norvegicus 150-159 7534490-8 1994 IL-1 beta-induced NO synthesis was significantly inhibited by NG-monomethyl-L-arginine, cycloheximide, actinomycin D, dexamethasone, and TGF-beta. Cycloheximide 88-101 interleukin 1 beta Rattus norvegicus 0-9 7536096-15 1995 Inhibition of protein synthesis with cycloheximide (Cx) abolished the loss in function that occurred over 2h in both control and IL-1 beta plus TNF-a-treated hearts.7. Cycloheximide 37-50 interleukin 1 beta Rattus norvegicus 129-138 7536096-15 1995 Inhibition of protein synthesis with cycloheximide (Cx) abolished the loss in function that occurred over 2h in both control and IL-1 beta plus TNF-a-treated hearts.7. Cycloheximide 52-54 interleukin 1 beta Rattus norvegicus 129-138 7980594-1 1994 In cultured rat aortic smooth muscle cells (RASMCs) IL-1 beta induced TGF-beta 1 mRNA expression, which was concentration (10 pM-10 nM)- and time (2-48 h) -dependent, and sensitive to cycloheximide. Cycloheximide 184-197 interleukin 1 beta Rattus norvegicus 52-61 8500722-11 1993 The IL-1 beta effect was also blocked by cycloheximide and was spontaneously reversible after 60 minutes. Cycloheximide 41-54 interleukin 1 beta Rattus norvegicus 4-13 7517798-11 1994 Cycloheximide and actinomycin D completely inhibited the IL-1 beta-induced NOx production and iNOS mRNA expression. Cycloheximide 0-13 interleukin 1 beta Rattus norvegicus 57-66 7524486-4 1994 Cycloheximide, an inhibitor of protein synthesis, prevented IL-1 beta-induced expression of iNOS mRNA, but not MnSOD mRNA. Cycloheximide 0-13 interleukin 1 beta Rattus norvegicus 60-69 8224206-3 1993 This effect of IL-1 beta on the cPLA2 activity is inhibited by actinomycin D and cycloheximide, indicating that both transcription and translation are involved. Cycloheximide 81-94 interleukin 1 beta Rattus norvegicus 15-24 8430802-4 1993 IL-1 beta also stimulated the cycloheximide-sensitive uptake of [35S] methionine uptake by the tissue. Cycloheximide 30-43 interleukin 1 beta Rattus norvegicus 0-9 1378338-11 1992 Myocytes possessed Ca(2+)-dependent NO synthase activity and expressed, after treatment with tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta), a Ca(2+)-independent NO synthase, the induction of which was prevented by dexamethasone and cycloheximide. Cycloheximide 262-275 interleukin 1 beta Rattus norvegicus 138-156 1334975-7 1992 IL-1 beta also induces the accumulation of cGMP by the insulinoma cell line Rin-m5F, and both NMMA as well as the protein synthesis inhibitor cycloheximide prevent this cGMP accumulation. Cycloheximide 142-155 interleukin 1 beta Rattus norvegicus 0-9 1378338-11 1992 Myocytes possessed Ca(2+)-dependent NO synthase activity and expressed, after treatment with tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1 beta), a Ca(2+)-independent NO synthase, the induction of which was prevented by dexamethasone and cycloheximide. Cycloheximide 262-275 interleukin 1 beta Rattus norvegicus 158-167 1661096-9 1991 The addition of cycloheximide to smooth muscle cells during their incubation with IL-1 beta completely inhibited smooth muscle cell nitrite production, the effects of the smooth muscle cells on platelet cGMP levels, and platelet responses to thrombin. Cycloheximide 16-29 interleukin 1 beta Rattus norvegicus 82-91 1648584-7 1991 The induction by rIL-1 beta was blocked by cycloheximide and dexamethasone. Cycloheximide 43-56 interleukin 1 beta Rattus norvegicus 17-27 1782324-6 1991 When islets were exposed for 12 h to 50 U/ml rIL-1 beta in the presence of either an inhibitor of gene transcription (actinomycin D) or an inhibitor of mRNA translation (cycloheximide) there was a complete protection against the suppressive effects of rIL-1 beta on insulin release, (pro)insulin biosynthesis and insulin mRNA contents. Cycloheximide 170-183 interleukin 1 beta Rattus norvegicus 45-55 1782324-6 1991 When islets were exposed for 12 h to 50 U/ml rIL-1 beta in the presence of either an inhibitor of gene transcription (actinomycin D) or an inhibitor of mRNA translation (cycloheximide) there was a complete protection against the suppressive effects of rIL-1 beta on insulin release, (pro)insulin biosynthesis and insulin mRNA contents. Cycloheximide 170-183 interleukin 1 beta Rattus norvegicus 252-262 1993692-8 1991 Inhibiting protein synthesis with cycloheximide blocked the effect of rIL-1 beta on elastin mRNA levels. Cycloheximide 34-47 interleukin 1 beta Rattus norvegicus 70-80